Fragile X Syndrome Clinical Trials 2023

What are the top hospitals conducting fragile x syndrome research?

When it comes to advancing the understanding and treatment of Fragile X Syndrome, several hospitals are leading the way with their groundbreaking clinical trials. In Chicago, Rush University Medical Center is at the forefront of research, currently conducting five active trials for Fragile X Syndrome. With a total of 17 trials dedicated to this condition since their first recorded trial in 2008, they have been making significant strides in unraveling the mysteries surrounding this genetic disorder. Meanwhile, Emory University School of Medicine in Atlanta has also emerged as a key player in Fragile X Syndrome research. They currently have four ongoing trials and have made notable contributions with six completed studies since beginning their first trial in 2018.

Notably contributing to these efforts is Suburban Research Associates located in Media, which has also undertaken four active fragile x syndrome clinical trials while adding valuable insights through nine previous investigations dating back to 2008. Furthermore Cincinnati Children's Hospital Medical Center based out of Cincinnati joins these ranks by actively running three clinical tests on fragile-X syndrome; having previously accomplished carrying out an additional nine experiments from recording its debut study back until2013.

Additionally adding itself onto this list is CHOC Thompson Autism Center situated excitingly nearly completing current analysis surrounding three cases pertaining towards fragile-x syndrome where all-time records align only starting2022. Fragile X Syndrome remains a complex condition that affects individuals worldwide and these top hospitals' dedication to pushing boundaries plays an integral role not only for patients but also for scientific progress as a whole. The cumulative impact achieved by each institution brings hope that we are moving closer toward effective treatments and improved quality of life for those living with Fragile X Syndrome

Which are the best cities for fragile x syndrome clinical trials?

In the realm of fragile x syndrome clinical trials, several cities have emerged as leading hubs for research and development. Cincinnati, Ohio takes the lead with 8 active trials exploring various interventions such as Study Drug, Speech Sounds, and Roflumilast. Chicago, Illinois follows closely behind with 7 ongoing studies focused on innovative treatments like Study Drug (BPN14770) and Methylphenidate. Sacramento, California shares a similar standing with 6 active trials investigating interventions including Study Drug and Methylphenidate. Atlanta, Georgia also boasts 6 active trials examining potential breakthroughs such as ZYN002 - Cannabidiol Transdermal Gel. Lastly, New york City offers individuals with fragile x syndrome access to cutting-edge clinical trials through its 6 ongoing studies involving Study Drug and ZYN002 - transdermal gel among others. Collectively these cities serve as epicenters for groundbreaking research aimed at improving the lives of those affected by this condition.

Which are the top treatments for fragile x syndrome being explored in clinical trials?

Exciting developments in clinical trials are shedding light on potential treatments for fragile X syndrome. Psilocybin, at a dosage of 1.5 mg, is currently being explored in one active trial dedicated to this condition. Its first listing occurred in 2023 and marks an important step forward in research efforts. Another promising treatment is roflumilast, which has also garnered attention with one active trial and was listed for the first time in 2022 specifically for fragile X syndrome studies. These innovative therapies hold promise as researchers strive to find effective interventions for individuals living with fragile X syndrome.

What are the most recent clinical trials for fragile x syndrome?

Promising advancements have been made in the field of fragile x syndrome, with recent clinical trials offering hope for individuals affected by this condition. Noteworthy studies include the investigation of psilocybin at a dosage of 1.5 mg in a Phase 2 trial, which became available on 3/28/2023. Additionally, methylphenidate has shown potential as a treatment option for fragile x syndrome patients and is currently being evaluated in a Phase 1 trial that became available on 2/1/2023. Another significant development involves the examination of Study Drug (BPN14770) in two separate Phase 3 trials, both initiated on 11/1/2022. Furthermore, roflumilast is being assessed through a Phase 2 trial since its availability on 9/8/2022. With these ongoing investigations into innovative therapies, there is renewed optimism for those living with fragile x syndrome and their families.

What fragile x syndrome clinical trials were recently completed?

Recent clinical trials have made significant strides in the quest for effective treatments for fragile X syndrome. In October 2021, Elizabeth Berry-Kravis completed a trial evaluating Ergoloid Mesylate as a potential therapy option. Another notable trial sponsored by Berry-Kravis investigated AFQ056 and concluded in August 2017. These studies mark important milestones in our understanding of fragile X syndrome and bring hope to individuals affected by this genetic disorder.